Blue Trust Inc. Grows Position in Certara, Inc. (NASDAQ:CERT)

Blue Trust Inc. raised its position in shares of Certara, Inc. (NASDAQ:CERT) by 112.3% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,925 shares of the company’s stock after buying an additional 2,076 shares during the quarter. Blue Trust Inc.’s holdings in Certara were worth $46,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in the company. Daventry Group LP lifted its stake in shares of Certara by 153.0% in the 2nd quarter. Daventry Group LP now owns 1,308,572 shares of the company’s stock valued at $18,124,000 after purchasing an additional 791,405 shares during the last quarter. Geneva Capital Management LLC lifted its stake in shares of Certara by 15.1% in the 1st quarter. Geneva Capital Management LLC now owns 4,404,199 shares of the company’s stock valued at $78,747,000 after purchasing an additional 579,349 shares during the last quarter. Kopion Asset Management LLC bought a new stake in shares of Certara in the 3rd quarter valued at approximately $4,457,000. Sei Investments Co. lifted its stake in shares of Certara by 39.5% in the 2nd quarter. Sei Investments Co. now owns 997,871 shares of the company’s stock valued at $13,821,000 after purchasing an additional 282,357 shares during the last quarter. Finally, Dimensional Fund Advisors LP lifted its stake in shares of Certara by 9.7% in the 2nd quarter. Dimensional Fund Advisors LP now owns 3,079,023 shares of the company’s stock valued at $42,643,000 after purchasing an additional 273,095 shares during the last quarter. Hedge funds and other institutional investors own 73.96% of the company’s stock.

Insider Activity

In other news, insider Leif E. Pedersen sold 51,224 shares of Certara stock in a transaction on Monday, September 9th. The stock was sold at an average price of $11.29, for a total value of $578,318.96. Following the transaction, the insider now directly owns 99,704 shares in the company, valued at approximately $1,125,658.16. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In related news, insider Patrick F. Smith sold 5,409 shares of the business’s stock in a transaction on Monday, October 7th. The stock was sold at an average price of $11.03, for a total transaction of $59,661.27. Following the transaction, the insider now directly owns 50,091 shares in the company, valued at $552,503.73. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Leif E. Pedersen sold 51,224 shares of the business’s stock in a transaction on Monday, September 9th. The stock was sold at an average price of $11.29, for a total value of $578,318.96. Following the transaction, the insider now owns 99,704 shares in the company, valued at approximately $1,125,658.16. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 2.39% of the company’s stock.

Certara Trading Up 0.5 %

CERT opened at $10.25 on Friday. The stock’s fifty day moving average is $11.22 and its two-hundred day moving average is $13.90. The company has a market capitalization of $1.65 billion, a P/E ratio of -20.50, a PEG ratio of 4.91 and a beta of 1.49. Certara, Inc. has a 52 week low of $9.99 and a 52 week high of $19.87. The company has a quick ratio of 2.61, a current ratio of 2.61 and a debt-to-equity ratio of 0.28.

Certara (NASDAQ:CERT) last announced its quarterly earnings results on Tuesday, August 6th. The company reported $0.07 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.03). Certara had a negative net margin of 21.64% and a positive return on equity of 3.03%. The company had revenue of $93.31 million during the quarter, compared to analysts’ expectations of $96.01 million. During the same quarter in the prior year, the business posted $0.10 earnings per share. The company’s revenue was up 3.2% compared to the same quarter last year. Analysts forecast that Certara, Inc. will post 0.27 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on CERT shares. UBS Group raised Certara from a “neutral” rating to a “buy” rating and set a $16.00 price target for the company in a research note on Friday, September 27th. Robert W. Baird decreased their price target on Certara from $19.00 to $18.00 and set a “neutral” rating for the company in a research note on Wednesday, August 7th. JMP Securities reissued a “market perform” rating on shares of Certara in a research note on Wednesday, July 10th. Barclays decreased their price target on Certara from $16.00 to $14.00 and set an “equal weight” rating for the company in a research note on Tuesday, October 15th. Finally, KeyCorp decreased their price target on Certara from $23.00 to $20.00 and set an “overweight” rating for the company in a research note on Thursday, July 11th. Six investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat, Certara presently has a consensus rating of “Hold” and a consensus price target of $17.08.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.